Table 2.
5 Year RFS Estimates | |||||
---|---|---|---|---|---|
N | Events | Survival | 95% CI | P-Value | |
All | 971 | 252 | 81.00% | (78.5%, 83.6%) | |
MET copy number | |||||
High | 82 | 29 | 72.60% | (63.5%, 83.1%) | |
Normal/Low | 889 | 223 | 81.80% | (79.3%, 84.5%) | 0.0637 |
PI3KCA copy number | |||||
High | 134 | 44 | 73.10% | (65.7%, 81.3%) | |
Normal/Low | 837 | 208 | 82.30% | (79.7%, 85.1%) | 0.154 |
Subtype | |||||
HER2-positive | 207 | 62 | 76.30% | (70.5%, 82.5%) | |
Hormone receptor-positive | 583 | 137 | 84.70% | (81.7%, 87.8%) | |
Triple receptor-negative | 173 | 49 | 74.20% | (67.8%, 81.3%) | 0.071 |
Age at Diagnosis | |||||
<50 | 371 | 123 | 77.40% | (73.2%, 81.9%) | |
>=50 | 595 | 129 | 83.30% | (80.3%, 86.5%) | 0.0003 |
Tumor size | |||||
<2cm | 566 | 116 | 86.50% | (83.6%, 89.5%) | |
>=2cm | 369 | 123 | 73.90% | (69.4%, 78.7%) | <0.0001 |
Nodal Status | |||||
Positive | 383 | 113 | 86.60% | (83.7%, 89.5%) | |
Negative | 565 | 130 | 73.90% | (69.5%, 78.6%) | <0.0001 |
Grade | |||||
1 | 92 | 22 | 85.00% | (77.8%, 92.9%) | |
2 | 477 | 113 | 83.30% | (79.9%, 86.9%) | |
3 | 336 | 95 | 77.50% | (73.0%, 82.2%) | 0.249 |
Menopausal Status | |||||
Peri/pre-menopausal | 312 | 101 | 76.30% | (71.5%, 81.3%) | |
Post-menopausal | 624 | 140 | 83.90% | (81.0%, 87.0%) | 0.0009 |
Stage | |||||
I | 304 | 43 | 91.90% | (88.8%, 95.1%) | |
II | 662 | 209 | 76.00% | (72.7%, 79.5) | <0.0001 |
Histology | |||||
Ductal | 898 | 235 | 80.70% | (78.0%, 83.4) | |
Other | 58 | 14 | 85.30% | (76.3%, 95.2%) | 0.826 |
Chemotherapy | |||||
No | 480 | 102 | 85.20% | (81.9%, 88.6%) | |
Anthracycline-based | 323 | 110 | 75.50% | (70.9%, 80.5%) | |
Anthracycline and Taxane-based | 114 | 24 | 81.60% | (74.6%, 89.2%) | 0.001 |
Radiation Therapy | |||||
Yes | 410 | 109 | 82.50% | (78.8%, 86.4%) | |
No | 535 | 134 | 80.60% | (77.2%, 84.2%) | 0.645 |
Endocrine Therapy | |||||
Yes | 422 | 79 | 87.30% | (84%, 90.6%) | |
No | 522 | 164 | 76.80% | (73.1%, 80.6%) | 0.0008 |